Background
==========

The WHO estimates there will be 2.3 billion overweight or obese adults world-wide by 2015; including 60% of adults and alarmingly 25% of children in developing countries <http://www.who.int>. This overweight and obesity epidemic is predicted to affect half the global population by 2025\[[@B1],[@B2]\], largely because of increased urbanization, adaptation of the western diet, and sedentary lifestyle, particularly in China and India.

A serious and nearly ubiquitous complication of obesity is defective insulin signalling in target tissues - skeletal muscle, liver, adipose tissue and brain. Insulin resistance unites obesity with a major disease cluster - diabetes, fatty liver and heart disease - through compensatory hyperinsulinaemia leading to pancreatic *β*-cell failure, and complicating dyslipidaemia and hypertension, major risk factors for CVD. T2D affects 150 million people world-wide, and is estimated to double by 2025\[[@B1],[@B2]\]. CVD is predicted to be the leading cause of death globally by 2020\[[@B3],[@B4]\]. Dementia and cancer are also more common in the obese\[[@B4],[@B5]\]. Therefore, understanding the mechanisms underlying obesity and insulin resistance is of great significance, as the need for new and more effective treatments grows.

Insulin resistance in obesity is causally associated with macrophage influx and low-grade, metabolic inflammation in adipose tissue. Macrophage-driven chronic inflammation in adipose tissue from the obese is considered to be triggered by endoplasmic reticulum (ER) and oxidative stress, together with hypoxia consequent on adiposity expansion and inadequate blood supply. Cellular stress leads to activation of stress kinesis and inflammatory effectors such as *Jnk*and *Nfkb*, with systemic release of cytokine and fatty acid mediators, which inhibit insulin signalling in target tissues\[[@B1]-[@B7]\].

While appetite, energy expenditure and metabolism are all critically regulated by hypothalamic brain circuits, white adipose tissue (WAT) is the major storage site for fat in the form of triglycerides, and therefore forms a repository balancing energy intake and expenditure. The overall adipose tissue burden of an individual is a combination of adiposity number (i.e. adipogenesis) and lipid load per cell (i.e. lipogenesis), and both processes may contribute to the adipose tissue mass in obesity.

*Nnat*is a paternally expressed imprinted gene first discovered in the developing brain and it is implicated in antenatal brain development and foetal growth\[[@B6]-[@B9]\]. In adult rodents and humans *Nnat*is highly expressed in neurons in many brain regions, including hypothalamic nuclei concerned with appetite regulation, and is concerned in nutrient sensing, and responds to feeding/fasting and leptin\[[@B10],[@B11]\]. *Nnat*is also highly expressed in adult white adipose tissue and aortic endothelial cells, where expression is increased in obese and diabetic rodents\[[@B12],[@B13]\]. *Nnat*is moreover expressed in pancreatic *β*-cell lines, where expression is glucose-dependent, and reduced in diabetic rodents\[[@B14]-[@B16]\]. By contrast *Nnat*expression in WAT is substantially reduced in lipodystrophic, in lean *S6kko*mice and in mice fed conjugated linoleic acid, which induces weight loss\[[@B16]-[@B18]\]. Recently a consistent association between single nucleotide polymorphisms in the human *Nnat*gene and severe obesity in both children and adults has been demonstrated\[[@B10]\]. This observation suggests that altered *Nnat*function in adipose tissue or the hypothalamic regions regulating energy homeostasis may be involved in the pathogenesis of human obesity.

*Nnat*has three exons, and resides within a large intron of *Blcap*\[[@B7],[@B8]\], tissue specific enhancers lie well upstream of the CpG-rich *Nnat*promoter. Knowledge about the upstream regulation of *Nnat*is confined to the β-cell and control by *NeuroD1*, a transcription factor important for neuronal and endocrine cell differentiation and survival\[[@B14]\].

Knowledge concerning downstream effecter mechanisms through which *Nnat*operates, and its physiological functions are limited. *Nnat*is an amphipathic proteolipid. It has two isoforms, α of 81 and *β*of 54 amino acids, generated by alternative splicing of the middle exon, encoding a membrane-binding domain\[[@B13]-[@B15],[@B19]\]. Both isoforms reside in the endoplasmic ER membranes, the *β*-isoform is implicated in ER stress and *β*-cell apoptosis\[[@B15]\], it is considered to regulate ER calcium ATPase through homology to other proteolipid. *Nnat*expression *in vitro*is associated with calcium-induced 3T3-L1 cell adipogenesis; glucose-stimulated, calcium-induced, insulin secretion from *β*-cells; activation of Pi3k, Erk, mTor and calcium signalling in medulloblastoma; *Nfkb-*regulated inflammation in aortic endothelial cells and protection against mitochondrial toxins and ionophores in *PC12*cells and resolution of injury after ischemic/reperfusion of the kidney \[[@B12]-[@B14],[@B19],[@B20]\].

The physiological roles of *Nnat*in the brain, pancreas, adipose and other tissues are not understood. Through genome-wide gene expression analysis we sought to improve our understanding of the mechanisms of *Nnat*regulation and its biological functions. First we carried out an integrated bioinformatics analysis of the conserved *Nnat*promoter in seven species and derived a candidate list of potential *Nnat*transcription factors. Then we interrogated multi-tissue gene expression data to look for primary evidence on the applicability of potential *Nnat*transcriptional regulators. We then used Gene Set Enrichment Analysis\[[@B21]\] to understand which biological functions are most highly correlated with *Nnat*expression. Finally, we generated a mouse protein-protein interaction network in adipose tissue to probe the biological relationships among genes forming a co-expression network with *Nnat*.

Methods
=======

Microarray datasets and meta-analysis
-------------------------------------

In this study, we used four different microarray gene expression datasets from WAT of *C57BL/6J*mice, as described below, to complete a meta-analysis. The first dataset designated BAIR was obtained as part of the Biological Atlas of Insulin Resistance (BAIR, <http://www.bair.org.uk>) project, a multi-lab collaborative effort to define gene expression changes involved in insulin signalling and resistance. Male mice were weaned at 3 weeks of age and fed a control chow diet containing 5% w/w fat, 19% protein and 3.5% fibre (S&K Universal Ltd, Hull, UK). At 5 weeks of age, a group of mice was transferred to 40% w/w high-fat diet, of which saturated fat is 40%, containing 32% pig fat, 8% casein fat, 19% protein, 21% glucose (Special Diet Services, Witham, UK) *ad libitum*, whereas the control group remained on chow. Mice fat-fed for 2 days, 8 days, 3 weeks and 15 weeks, and with age-matched controls, were killed and epididymal WAT was obtained for microarray gene expression studies, employing *Affymetrix*mouse genome 4302 microarray. From these four time points a total of 40 Affymetrix gene expression raw *CEL*files were produced and *RMA*normalized by using the *Affy*package <http://www.bioconductor.org>; present/absent call information was also calculated based on *Affymetrix MAS5*algorithm. This dataset has been deposited in EBI ArrayExpress Database with accession number E-BAIR-12 <http://www.ebi.ac.uk/microarray-as/ae/>.

The second dataset was obtained from the Gene Expression Omnibus (GEO, <http://www.ncbi.nlm.nih.gov/geo/>, accession ID: GSE4671), which contains 28 Affymetrix mouse genome 4302 chips. Nine-week old male mice in this experiment were fed with either a control chow diet or a chow diet that also contained 0.5% conjugated linoleic acid (*CLA*). At each of seven time points (day 1, 2, 3, 4, 7, 10, 17), retroperitoneal WAT was obtained from two control mice and two test mice. Microarray data were processed using GCRMA algorithm.

The third dataset was also acquired from GEO with accession number GSE8831, in which 20 female and 15 male C57BL/6J mice, fed by *ad libitum*, varied in body weight and insulin sensitivity were studied. Fasting blood glucose and serum insulin concentrations were measured 2-4 days prior to collection of adipose tissue. *RNA*from perigonadal adipose tissue was extracted and processed for analysis on *Affymetrix Mu74Av2*microarrays. *RMA*normalization was applied to the 35 raw CEL files, and *MAS5*present/absent call information was calculated as well.

The fourth dataset consisted of 13 *Affymetrix MG-U74av2*chips for epididymal WAT extracted from six-week old C57BL/6J male mice from the Diabetes Genome Anatomy Project DGAP <http://www.diabetesgenome.org>. There were four high-fat feeding mice (derives 55% calories from fat, 21% calories from protein, 24% calories from carbohydrates), nine low-fat feeding control mice (derives 14% calories from fat, 25% calories from protein and 61% calories from carbohydrates). Gene expression data was *RMA*normalized with present/absent call information.

In order to identify the gene co-vary with *Nnat*in WAT, we calculated Pearson correlation coefficients between the expression of *Nnat*and all other genes in each of the above four datasets separately, and chose genes showing the highest correlation with *Nnat*expression. Subsequently, rather than merely combining the p-values of the Pearson correlation coefficients, we used weighted unbiased Pearson statistical values, i.e. we normalized the statistical values to approximate a normal distribution with unit variance and zero mean. Some necessary filters were designed for quality control: (a) probesets with expression value lower than 100 or (b) absolute Pearson value less than 0.2 or (c) present/absent call less than 30% were excluded. Each gene was represented by the probesets which had the largest absolute Pearson correlation in each dataset in order to remove multiple annotated probesets for the same gene. In this way we obtained 2841, 3061, 2148 and 1201 unique genes within the four datasets respectively, giving 6120 unique genes in total.

The following formula was applied to calculate the combined *Z-score*

$$Z_{score} = {{\sum\limits_{i = 1}^{4}\left( {\sqrt{\omega_{i}} \times T_{i}} \right)}/\sqrt{\sum\limits_{i = 1}^{4}\omega_{i}}}$$

*ω~i~*denotes the number of samples in each dataset (i.e. 40, 28, 35, 13); *T~i~*indicates the normalized Pearson association test statistic based on a *t*distribution. A two-tailed *P*-value can be derived by the normal distribution for each gene from this combined *Z~score~*. *Bonfferroni*corrected *FDR*\< 0.05 was applied, yielding the top 34 genes which are most strongly co-expressed with *Nnat*. For comparison we also applied *Fisher\'s*Z-transform to combine the transformed Pearson correlation coefficients in the meta-analysis, we got similar results. For the multi-species analysis, seven genes, *Acp5, Tcta, Znrf2, Serpina3c, S3-12, Sgce*and *Lrg1*, which are not conserved in rat, were excluded.

Promoter analysis
-----------------

To delineate the *Nnat*promoter, we identified the conserved non-coding region of the *Nnat*locus in seven mammalian genera (*Pan, Bos, Canis, Mus, Sus, Rattus*and *human*). This corresponds to 1200 *bp*upstream and 800 *bp*downstream of the most utilized transcription start points (TSP) of *Nnat*, identified through the presence of CAGED transcripts in mice and human. For example, mouse *Nnat*has six transcripts, with two promoters having respectively 36 and 28 CAGE tags, while human *NNAT*has four transcripts with one promoter having 29 CAGE tags. For these analyses we used the Genome VISTA genome alignment tool <http://www-gsd.lbl.gov/vista/> in conjunction with *Genomatix Gene2promoter*tool (*Genomatix*Software Inc., Ann Arbor, MI, USA). The *Genomatix MatInspector*programme with default parameter settings was used to detect common Transcription Factor Binding Sites (TFBS) between the seven promoter sequences of the seven genera. The occurrence of the TFBSs within all vertebrate genes was used as a control in *MatInspector*. Significant common TFBSs among the seven species were defined by having a p-value \< 0.05 and presence in six or more species, compared with the control sets in the *Genomatix*database. We further explored the TF genes in each TFBSs family, examining expression data to determine whether they were expressed in human or mouse adipose, hypothalamus and pancreas islet (using *BioGPS*database <http://biogps.gnf.org> and our own BAIR data as reference sources). Promoter analysis was also applied to these 27 fully conserved *Nnat*co-expression genes (plus *Nnat*) all together, focusing on human, mouse and rat only. Again, their expression status in adipose, hypothalamus and pancreatic islets were included as well.

Gene set enrichment analysis
----------------------------

In order to inspect which biological pathways are significantly correlated with *Nnat*expression in adipose tissue, we employed Gene Set Enrichment Analysis, using the GSEA package <http://www.broadinstitute.org/gsea/> for each of the above four datasets separately. We chose Pearson correlation and permuted 1000 times to detect statistical significance. Expression data were pre-filtered by using the present/absent call and background correction, similarly to the pre-process in meta-analysis above. In the GSEA database there were 200 *KEGG*pathway sets and 639 canonical pathway sets. We first focused on those approximately 100 *KEGG*gene sets which have more than 15 genes and fewer than 500 genes; the results returned were significant in the above four datasets as well as an additional dataset which included 45 sleep mice model with hypothalamus tissue (GEO: GSE6514). We then worked on those canonical pathway sets which passed the same filter only on BAIR fat-fed mice and human fat dataset about 20 lean and 19 obese person\[[@B22]\].

Protein-protein interaction network analysis
--------------------------------------------

By using BioNetBuilder, a cytoscape plugin package <http://err.bio.nyu.edu/cytoscape/bionetbuilder/> with supported databases DIP, BIND, Prolinks, KEGG, HPRD, The BioGrid and GO, we thus generated a mouse protein-protein interaction network which had 11777 unique nodes (genes) and 107813 unique edges (links). For the 27 fully conserved *Nnat*co-expression genes, we searched each of their direct correlation genes (first neighbours) in the PPI network, again filtered by expression value \> 200 in adipose tissue by *BioGPS*.

Results
=======

*Nnat*promoter analysis
-----------------------

We sought to investigate mechanisms of transcriptional regulation of *Nnat*and of co-varying genes in adipose tissue. The neuronatin gene is located on human chromosome 20 and mouse chromosome 2. To define the *Nnat*promoter we described the conserved non-coding region in seven mammalian species, including mouse and human, corresponding to 1200 bp upstream and 800 bp downstream of the most utilized transcription start points (TSP) of *Nnat*identified through the presence of CAGED transcripts in mice and humans. We used *Genomatix*software to determine the presence of binding sites for TF families in the conserved *Nnat*promoter, across seven mammalian species. We then filtered these potential regulators based on their expression in mouse WAT, and compared their expression also in hypothalamus and pancreatic *β*-cells in which *Nnat*is known to be expressed. Table [1](#T1){ref-type="table"} shows the gene expression behaviour for members of TFBS families scoring as significant for presence in the *Nnat*promoter (p-value \< 0.05), and present in at least six of the *Nnat*promoter sequences; expression values were filtered on the basis of *BioGPS*expression bigger than 200, which therefore focuses attention on the most abundantly expressed TFs.

###### 

Expression of conserved TFBS in Nnat promoter

  TFs      TFBSs     p-value   WAT     hypo   panc   TFs       TFBSs     p-value   WAT    hypo   panc
  -------- --------- --------- ------- ------ ------ --------- --------- --------- ------ ------ ------
  Pparγ    V\$PPAR   0         11959   253    357    Hsf2      V\$HEAT   0.0202    271    543    279
  Zfp161   V\$ZF5F   2E-05     1309    1537   523    Tef       V\$PARF   0.0209    4845   5297   846
  Rreb1    V\$RREB   0.0005    3530    1344   117    Myb       V\$MYBL   0.0217    730    51     81
  Tead4    V\$TEAF   0.0005    271     239    367    Meox2     V\$HBOX   0.0221    555    37     47
  Hes2     V\$HESF   0.0016    468     304    498    Stat3     V\$STAT   0.0236    3754   1438   617
  Gtf2i    V\$DICE   0.002     5309    7006   398    Myt1l     V\$MYT1   0.0247    327    1039   395
  Zfp384   V\$CIZF   0.0023    1966    989    1073   Neurod1   V\$NEUR   0.0262    119    323    224
  Myog     V\$MYOD   0.0024    523     524    638    Neurod2   V\$NEUR   0.0262    209    216    237
  Glis2    V\$GLIF   0.0026    308     365    390    Hand1     V\$HAND   0.0283    557    519    662
  Mef2d    V\$MEF2   0.0027    2451    4184   668    Bcl6      V\$BCL6   0.0301    4569   1672   82
  Tcf7l2   V\$LEFF   0.0033    4252    1922   329    Gata3     V\$GATA   0.0323    432    54     72
  Ctcf     V\$CTCF   0.004     2655    1586   890    Pbx2      V\$PBXC   0.0345    524    456    253
  Srf      V\$SRFF   0.0041    340     275    212    Hoxd9     V\$ABDB   0.0364    230    139    190
  Zfp219   V\$ZBPF   0.0042    1282    1712   270    Hoxc8     V\$HOXF   0.0371    1804   203    364
  Hif1a    V\$HIFF   0.0042    542     564    194    Evi1      V\$EVI1   0.0412    274    240    335
  Mlxipl   V\$EBOX   0.006     304     27     32     Creb1     V\$CREB   0.0415    2387   1157   532
  Nfat5    V\$NFAT   0.0069    1154    842    203    Jun       V\$CREB   0.0415    2503   1955   1735
  Egr2     V\$EGRF   0.0078    408     141    289    Klf15     V\$KLFS   0.0419    7360   2193   2438
  Tfdp1    V\$E2FF   0.0125    1993    1575   77     Klf4      V\$KLFS   0.0419    4878   593    348
  Pou6f1   V\$BRN5   0.0146    632     973    446    Klf6      V\$KLFS   0.0419    3219   583    895
  Sp1      V\$SP1F   0.0147    322     200    306    Foxo1     V\$FKHD   0.0424    400    129    106
  Dmrt2    V\$DMRT   0.0157    275     28     57     Sox4      V\$SORY   0.043     4829   1217   74
  Nfyc     V\$CAAT   0.0161    2207    914    247    Pou2f1    V\$OCT1   0.0443    225    229    238
  Irf1     V\$IRFF   0.0166    5486    259    196    Elf1      V\$ETSF   0.0464    2419   78     134
  Ahr      V\$AHRR   0.0171    483     135    62     Nr2f2     V\$NR2F   0.0472    6090   8397   259
  Nfia     V\$NF1F   0.0171    3505    2335   505    Rxrb      V\$RXRF   0.0479    1715   1309   1944
  Lhx4     V\$LHXF   0.0177    269     242    225    Msx1      V\$HOMF   0.0479    392    360    435

Conserved TFBS found in ***Nnat***promoter region across seven mammalian species and their gene expression in three tissues of mice.

The TFBS for the *V\$NEUR*family (including *NeuroD1*and *NeuroD2*) was found to be highly significant in six out of seven promoter sequences, but it was not found in the rat promoter sequences in our defined region. However, *V\$NEUR*does exist farther upstream from the rat *Nnat*transcription start site (within 2.5kb). *NeuroD1*, the only confirmed transcriptional regulator of *Nnat*expression\[[@B14]\] is not one of the most highly expressed *TFs*in adipose, though its expression value is similar across all three tissues shown in Table [1](#T1){ref-type="table"}, it is highly expressed in cerebellum.

The binding sites for the key adipose tissue regulator *Pparγ*are the most significant in the seven *Nnat*promoter sequences. Of the TFs with conserved binding sites it is also by far the most highly expressed in WAT, and has a crucial role in adipocyte metabolism. Other important TFs with conserved binding sites in the *Nnat*promoter and which are highly expressed in WAT include several genes which have crucial roles in the control of: adipogenesis (*Klf15, Irf1, Creb1, Egr2, Gata3*); lipogenesis (*Mlxipl*, *Srebp1c*); inflammation (*Jun, Stat3*); insulin signalling and diabetes susceptibility (*Foxo1, Tcf7l2*). Interestingly, the *Rreb1*has a binding site in all seven *Nna*t promoters, and is expressed at high levels in adipose and hypothalamus. *Rreb1*can enhance the transcription-activating function of *NeuroD1*, a property that requires both the physical interaction of *Rreb1*with *NeuroD1*, and binding *of Rreb1*to *DNA*\[[@B23]\]. Notable by their absence are binding sites for the C/EBP family of TFs, clearly suggesting that this family (several members of which are required for adipocyte differentiation) are not concerned with *Nnat*regulation, and may be down-stream of *Nnat*.

Identification of biological pathways associated with *Nnat*expression
----------------------------------------------------------------------

In order to determine which biological pathways are significantly correlated with *Nnat*expression in WAT and hypothalamus, we employed Gene Set Enrichment Analysis. Initially we focused on *KEGG*pathways to investigate those processes that are most highly associated with *Nnat*expression in WAT and hypothalamus. In WAT, there are five *KEGG*pathways significantly correlated with *Nnat*expression (FDR \< 0.05) in at least two of the four mouse WAT datasets (Table [2](#T2){ref-type="table"}), these five pathways are all significant in BAIR fat-fed data, and include oxidative phosphorylation, ribosome, proteasome, cholera infection and neuroactive ligand receptor interaction, these last two indicating perturbation of ion transport and neuronal function. Furthermore, oxidative phosphorylation, ribosome and cholera infection are significant in the mouse hypothalamus dataset as well. Additional file [1](#S1){ref-type="supplementary-material"}, **Figure S1**illustrates the enrichment plots and positively and negatively correlated genes in these three common pathways. Additional file [1](#S1){ref-type="supplementary-material"}, **Table S1**lists the core enriched genes that correlate with *Nnat*in these three common pathways in both WAT and hypothalamus. GSEA on the canonical pathways (Additional file [1](#S1){ref-type="supplementary-material"}, **Table S2**) reveals that *Nnat*expression in mice on a high-fat diet and obese models displayed highly positive correlations with inflammatory pathways (complement and coagulation, cytokine and integrin signalling), and strongly negative correlations with metabolic pathways (most prominently oxidative phosphorylation, pyruvate metabolism, glycolysis and gluconeogenesis) and protein turnover (including proteasome, ribosome and mRNA processing). In human adipose tissue *NNAT*mRNA expression is decreased (Additional file [1](#S1){ref-type="supplementary-material"}, **Table S3**). In consequence *NNAT*expression displayed strong positive correlation with genes involved in protein turnover and fatty acid metabolism/degradation, and negatively correlated with genes involved in adhesion, complement and coagulation and cytokine. Additional file [1](#S1){ref-type="supplementary-material"}, **Table S4**lists the common pathways correlated with *Nnat*expression between BAIR fat-fed mice and human obese WAT, and these are concerned with cytokine signalling and cell-cell interaction. Additional file [2](#S2){ref-type="supplementary-material"}, **Table S5**contains the complete list of genes associated with *Nnat*in each *KEGG*pathway in mouse models.

###### 

Pathways associated with Nnat

  *KEGG*Pathway                                Size   p-value    FDR        Correlation   Tissue
  -------------------------------------------- ------ ---------- ---------- ------------- --------
  OXIDATIVE_PHOSPHORYLATION                    92     \< 0.001   \< 0.001   Negative      WAT
  RIBOSOME                                     52     \< 0.001   \< 0.001   Negative      WAT
  PROTEASOME                                   22     \< 0.001   \< 0.001   Negative      WAT
  CHOLERA_INFECTION                            33     \< 0.001   \< 0.01    Negative      WAT
  NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION      36     \< 0.001   \< 0.01    Positive      WAT
  OXIDATIVE_PHOSPHORYLATION                    93     \< 0.001   0.011      Negative      Hypo
  RIBOSOME                                     52     \< 0.001   0.006      Negative      Hypo
  CHOLERA_INFECTION                            32     \< 0.001   0.031      Positive      Hypo
  ALANINE_AND_ASPARTATE_METABOLISM             25     \< 0.002   0.029      Positive      Hypo
  ARGININE_AND_PROLINE_METABOLISM              18     \< 0.001   0.026      Positive      Hypo
  TRYPTOPHAN_METABOLISM                        31     \< 0.001   0.025      Positive      Hypo
  SELENOAMINO_ACID_METABOLISM                  21     0.004      0.029      Positive      Hypo
  THYROID_CANCER                               21     0.003      0.025      Positive      Hypo
  BUTANOATE_METABOLISM                         29     0.004      0.036      Positive      Hypo
  GALACTOSE_METABOLISM                         16     0.006      0.04       Positive      Hypo
  GLYCOLYSIS_AND_GLUCONEOGENESIS               30     0.004      0.05       Positive      Hypo
  PATHOGENIC_ESCHERICHIA_COLI_INFECTION_EHEC   24     0.008      0.049      Positive      Hypo

Significant pathways associated with *Nna*t analyzed by GSEA.

Identification of genes that co-vary with Nnat
----------------------------------------------

The genes whose expression co-varies with *Nnat*are likely to share regulatory mechanisms and, perhaps, biological functions. We therefore identified genes whose expression is highly correlated with *Nnat*in a meta-analysis of WAT gene expression data. Table [3](#T3){ref-type="table"} shows the correlation of gene expression behaviour with that of *Nnat*, in four microarray datasets; entries with a null value indicate that this gene is missing in the specific dataset; their fold change information in BAIR fat-fed mice and human with obesity are shown in Table [4](#T4){ref-type="table"}. Additional file [1](#S1){ref-type="supplementary-material"}, **Figure S2**gives the hierarchical clustering for these 28 genes in BAIR fat-fed dataset, here genes with expression most closely associated with *Nnat*include *Aqp1, Sncg, Sulf2*and *Cxcl9*. Additional file [1](#S1){ref-type="supplementary-material"}, **Figure S3**illustrates the expressions of the top four most correlated genes (*Gstt1, Ccdc80, Hfe Sod3*) with *Nnat*in BAIR and GSE6571 datasets. Among these genes is only one transcription factor, *Ebf1*which has previously been suggested to have a regulatory role in adipogenesis\[[@B24]\]. Another of the *Nnat*-correlated genes, *Lgals12*, is a member of the galectin family of beta-galactoside-binding proteins, and is a major regulator of adipose tissue development\[[@B25]\].

###### 

Co-expression genes with Nnat in WAT

  Genes      GSE8831   GSE4671   BAIR   DGAP   meta.z   p-value    FDR
  ---------- --------- --------- ------ ------ -------- ---------- ----------
  GSTT1      0.33      0.92      0.87   0.71   6.16     7.50E-10   4.59E-06
  CCDC80     0.36      0.93      0.86          5.82     5.85E-09   3.58E-05
  HFE        0.71      0.93      0.71          5.81     6.37E-09   3.90E-05
  SOD3       0.64      0.84      0.79   0.51   5.55     2.93E-08   0.0002
  NPDC1      0.67      0.92      0.62   0.7    5.44     5.47E-08   0.0003
  AQP1       0.68      0.71      0.8    0.47   5.37     7.73E-08   0.0005
  EBF1       0.62      0.84      0.81          5.3      1.15E-07   0.0007
  SNCG       0.81      0.58      0.72          5.28     1.30E-07   0.0008
  LGALS12              0.95      0.83          5.15     2.57E-07   0.0016
  SLC6A13    0.73      0.8       0.7    0.4    5.1      3.43E-07   0.0021
  HEBP1      0.73      0.84      0.69          5.09     3.53E-07   0.0022
  NPR3       0.66      0.71      0.77   0.54   5.07     4.04E-07   0.0025
  RAD50      0.63      0.35      0.85          5.06     4.16E-07   0.0025
  H6PD       0.54      0.85      0.77   0.53   5.04     4.57E-07   0.0028
  HTRA3      0.48      0.95      0.67          5.01     5.76E-07   0.0035
  ART3       0.63      0.81      0.77          4.95     7.28E-07   0.0045
  CAV1       0.67      0.73      0.78          4.95     7.46E-07   0.0046
  AOC3       0.27      0.95      0.76   0.25   4.94     7.73E-07   0.0047
  ANXA6      0.65      0.73      0.73   0.57   4.84     1.29E-06   0.0079
  CXCL9      0.33      0.53      0.88          4.71     2.51E-06   0.0154
  JUP        0.55      0.79      0.62   0.89   4.7      2.60E-06   0.0159
  BLCAP      0.5       0.9       0.61   0.76   4.65     3.30E-06   0.0202
  FZD4       0.49      0.73      0.79   0.5    4.63     3.62E-06   0.0221
  SULF2                0.88      0.86          4.63     3.68E-06   0.0226
  CD151                0.83      0.87   0.46   4.62     3.79E-06   0.0232
  MAP1LC3A   0.68      0.78      0.59   0.67   4.56     5.05E-06   0.0309
  EPN2       0.54      0.91      0.53   0.71   4.48     7.42E-06   0.0454

High significant co-expression genes with *Nnat*in WAT based on gene expression meta-analysis. This table shows the Pearson correlation coefficient value of each gene in each of the four microarray datasets, blank value means that the relevant gene is not expressed (not passed the QC or even not included into the microarray chip). Top combined meta-zscore, meta-pvalue and FDR test are shown by FDR \< 0.05.

###### 

The fold change of co-expression genes

  Genes      BAIR.2d   BAIR.8d   BAIR.3w   BAIR.15w   Human
  ---------- --------- --------- --------- ---------- -------
  NNAT       7.82      3.54      1.02      1.19       0.72
  GSTT1      2.5       1.43      1.1       0.89       0.86
  CCDC80     2.65      2.2       0.69      1.05       2.57
  HFE        1.59      1.16      0.77      1.34       0.87
  SOD3       1.99      1.64      0.87      1.45       0.89
  NPDC1      1.28      1.14      0.92      0.96       1.88
  AQP1       1.64      1.32      1.27      1.01       1.52
  EBF1       2.07      1.54      0.89      1.28       0.68
  SNCG       6.16      8.06      1.53      1.53       1.26
  LGALS12    3.12      1.47      0.89      0.93       1.03
  SLC6A13    2.09      1.74      0.54      1.89       0.77
  HEBP1      1.35      1.18      0.77      1          1.08
  NPR3       5.28      3.14      0.7       2.87       1.69
  RAD50      2.02      1.67      0.85      1.24       0.71
  H6PD       1.82      1.38      1.05      0.95       1.16
  HTRA3      1.65      1.23      0.8       1.27       1.12
  ART3       2.03      1.41      0.92      0.88       1.33
  CAV1       1.48      1.18      0.88      1.14       0.93
  AOC3       1.91      1.11      0.75      1.37       0.83
  ANXA6      1.64      1.59      0.97      1.4        0.85
  CXCL9      3.48      2.3       1.26      1.25       1.22
  JUP        1.54      1.07      0.89      1          1.06
  BLCAP      1.58      1.11      1.03      1.1        0.92
  FZD4       2.24      1.42      0.88      1.9        1.11
  SULF2      1.59      1.31      1         1.11       2.08
  CD151      1.54      1.23      0.95      1.18       1.1
  MAP1LC3A   1.32      0.95      1.03      1.32       0.93
  EPN2       1.14      1.03      1.18      1.17       1.24

This table shows the fold change (FC) of those co-expression genes of Nnat in adipose tissue in fat-fed mice during development of diet-induced obesity, and in human obese adipose tissue.

In order to investigate whether these 27 genes share conserved TFBS with *Nnat*as identified in Table [1](#T1){ref-type="table"}, we used *Genomatix*tools to analyze the promoters of all 28 genes in human, mouse and rat separately. We found that nine TFBS families in Table [1](#T1){ref-type="table"}, *V\$CREB, V\$EVI1, V\$GATA, V\$KLFS, V\$NR2F, V\$RXRF, V\$SORY, V\$STAT, V\$HAND*, which are conserved in the promoter region of *Nnat*from seven species, are significant TFBS of all these 28 genes in human, mouse and rat, indicating these TFBSs are likely to be important in WAT. We also found that *V\$RREB*and *V\$TEAF*are highly significant TFBS*s*(p-value \< 3.31e-10, p-value \< 6.22e-8, p-value \< 5.58e-7) in most of the 28 genes, while *V\$PPAR*is highly significant (p-value \< 5.7e-4, p-value \< 4.14e-6, p-value \< 5.7e-4) half in of the 28 genes (Table [5](#T5){ref-type="table"}).

###### 

Common TFBS among Nnat and its co-vary genes

  TFBS      hs_pval    mm_pval    rat_pval   \#hs   \#mm   \#rat
  --------- ---------- ---------- ---------- ------ ------ -------
  V\$PPAR   5.70E-04   4.14E-06   5.70E-04   12     15     12
  V\$ZF5F   1.62E-06   2.34E-04   0.0033     18     15     13
  V\$RREB   3.31E-10   6.22E-08   5.58E-07   26     24     23
  V\$TEAF   6.22E-08   6.22E-08   5.34E-09   24     24     25
  V\$STAT   9.89E-09   1.29E-07   8.77E-06   26     25     23
  V\$HESF   2.35E-09   4.30E-08   2.83E-05   27     26     23
  V\$MYOD   1.29E-08   1.69E-05   9.92E-05   27     24     23
  V\$GLIF   5.36E-09   3.90E-06   3.00E-07   28     26     27
  V\$MEF2   0.0025     2.52E-05   0.0025     21     24     21
  V\$LEFF   0.0042     5.25E-05   2.80E-04   21     24     23
  V\$CTCF   9.37E-05   1.43E-05   1.59E-06   24     25     26
  V\$SRFF   1.50E-05   0.002      1.67E-06   25     22     26
  V\$ZBPF   1.23E-06   2.30E-08   1.23E-06   27     28     27
  V\$HIFF   2.45E-07   8.69E-12   2.45E-07   22     26     22
  V\$EBOX   8.80E-06   6.89E-05   1.34E-08   26     25     28
  V\$NFAT   5.79E-05   5.79E-05   0.0025     27     27     25
  V\$EGRF   1.84E-04   2.35E-06   1.84E-04   25     27     25
  V\$SP1F   8.94E-06   8.94E-06   8.94E-06   27     27     27
  V\$CAAT   2.19E-06   2.19E-06   1.00E-04   28     28     27
  V\$CART   0.0029     0.0029     0.0029     25     25     25
  V\$IRFF   6.53E-04   0.0034     6.53E-04   26     25     26
  V\$NF1F   4.37E-06   5.72E-08   4.37E-06   23     25     23
  V\$AHRR   6.01E-07   6.07E-08   1.42E-04   24     25     21
  V\$HEAT   0.0015     2.07E-04   2.07E-04   26     27     27
  V\$MYBL   0.0021     3.12E-04   7.05E-06   26     27     28
  V\$STAT   1.38E-05   1.38E-05   1.38E-05   28     28     28
  V\$NEUR   1.64E-04   2.64E-05   3.09E-06   24     25     26
  V\$HAND   2.30E-04   2.30E-04   2.30E-04   28     28     28
  V\$BCL6   5.24E-06   0.0027     3.39E-05   24     20     23
  V\$GATA   6.49E-05   6.49E-05   6.49E-05   28     28     28
  V\$EVI1   3.23E-04   3.23E-04   3.23E-04   28     28     28
  V\$CREB   3.64E-04   3.64E-04   3.64E-04   28     28     28
  V\$KLFS   6.56E-04   6.56E-04   6.56E-04   28     28     28

The common TFBS among the 28 (*Nnat*and its co-vary) genes in three species respectively. The last three columns give the number of promoter sequences among the 28 which share the same TFBS in their promoter sequences

We used the *Genomatix*Promoter Module Library and were able to identify highly conserved models of five transcription factor elements highly conserved across the *Nnat*promoter. Among these promoter sequences, we got 20 significant models which consist of elements from five transcription factor family. Figure [1](#F1){ref-type="fig"} shows TFBPs for V\$EVI1 - V\$EGRF - V\$E2FF - V\$NRF1 - V\$LEFF, on the *Nnat*promoter close together in a similar region for six species separately just upstream of the major TSP. V\$EVI1 - V\$EGRF - V\$E2FF and -V\$LEFF are in Table [1](#T1){ref-type="table"} and TF members of these families are expressed in WAT, hypothalamus and pancreas. V\$EVI1 - V\$EGRF and - V\$LEFF in Table [5](#T5){ref-type="table"} indicate conservation in the promoters of genes that co-vary with *Nnat*. There are important transcription factors in these families, for example *Egr2*and *Tcf7l2*, which are implicated in stress responses and T2D; *E2f*which is concerned with adipogenesis and *Evi1*, which activates *Stat3*, a transcription factor concerned with leptin signalling in the hypothalamus.

![**Transcription factor module in six *Nnat*promoter sequences**. There are 20 significant five-element modules found in the six promoter sequences of *Nnat*for six species (Human, Mus, Can, Sus, Bos, Rat), sequence in 1200 bp upstream and 800 bp downstream, here shows TFBSs for V\$EVI1 - V\$EGRF - V\$E2FF - V\$NRF1 - V\$LEFF, on the *Nnat*promoter closely and together in the similar region of the six species separately just upstream of the major TSP.](1752-0509-4-175-1){#F1}

Functional networks formed by genes that co-vary with Nnat
----------------------------------------------------------

In the mouse PPI network, we sought *Nnat*, and the 27 genes that co-vary with it, and their respective first neighbours. 21 of the 27 *Nnat*co-expression genes can be mapped to this PPI network, which contains 375 first neighbours, leading to a sub-network with a total of 396 nodes and 3804 edges. Among these genes, 191 (48%) are expressed in hypothalamus (including 11 of the 21 *Nnat*co-varying genes) and 275 (69%) are expressed in WAT (including all 21 of the *Nnat*co-expression genes), 190 (48%) are expressed in pancreas (including 8 of the 21 *Nnat*co-varying genes, all expressed in hypothalamus as well). The functional groups formed by the PPI involving the 21 *Nnat*co-varying genes (examples given in parentheses with sentinel gene emboldened) correspond to the following major biological functions: (1) cellular stress, inflammation, adipocyte metabolism, metabolic syndrome and type 2 diabetes (*Sncg, Erk1/2, Jnk, Hnf4a*and *Fabp4*); (2) detoxification of aldehydes, retinol and products of oxygen free radical metabolism (*Aoc3, Aldh1a3/9a*1, *Rdh11/12/13*); (3) local natriuretic peptide system and growth (*Npr3, Nppa*); (4) glutathione and xenobiotic metabolism (*Gstt1/3, Cyp1a1/1b1*); (5) iron metabolism (*Hfe*and *Tfrc*); (6) *Wnt*signaling (*Fzd6, Sfrp1*and *Wtn11*); (7) adipogenesis (*Ebf1, Ebf4, Crebbp, Ep300*); (8) protein turnover (*Rad50, Eif4a1, Psmc4*and *Ube2b*); (9) integrins, neurodegeneration, and metabolic, inflammatory and growth-control signalling (*Cav1, Ngfr, Tnfrsf1b, Hras1, Pten, App, Hnf4a*and *Esr*). Figure [2](#F2){ref-type="fig"} shows a sub-network with genes expressed in WAT, hypothalamus and pancreatic β-cells, which has 151 nodes and 447 links. Eight genes that co-vary with *Nnat*in the three tissues are shown in yellow, and comprise: *Anxa6, Cav1, Cd151, Gstt1, Map1lc3a, Npdc1, Npr3, and Sncg*. *Nnat*does not appear since it is not included in the mouse PPI database.

![**Mouse *Nnat*co-expression gene tissue-specific PPI network**. All ***Nnat***co-expression genes in Table 3 and their first neighbours in mouse PPI network showing expressed in WAT, hypothalamus and pancreas, generated a tissue-specific network with 151 nodes and 447 links. The eight genes in yellow are ***Nnat***co-varying genes in Table 3. Two obesity relative genes ***App***and ***Tcf7l2***and their direct associated genes linked by red edges.](1752-0509-4-175-2){#F2}

Discussion
==========

This study explored the behaviour of the diet-responsive gene *Nnat*in multiple gene expression datasets from mouse adipose tissue, and subsequently analysed *in silico*the promoter of *Nnat*in seven mammalian species. Rosen and MacDougald\[[@B24]\] have pointed out that at least 100 TFs are expressed in adipocyte, and our analyses here have sought to focus attention on those which could play a part in the regulation of expression of *Nnat*and its co-varying genes. Based on our study we find 50 TFBSs conserved across seven species on the *Nnat*promoter, and expression of the TFs corresponding to these in adipose tissue, many of which have known roles in adipocyte processes including, adipogenesis (*Klf15, Irf1, Creb1, Egr2, Gata3*); lipogenesis (*Mlxipl, Srebp1c*); inflammation (*Jun, Stat3*); insulin signalling and diabetes susceptibility (*Foxo1, Tcf7l2*). These TFs are also well expressed in the hypothalamus and pancreas.

*NeuroD1*is the only confirmed transcription factor for *Nnat*, whose expression regulates in the developing pancreas\[[@B14]\]. Binding sites for the TF family *V\$NEUR*(which includes *NeuroD1*and *NeuroD2*) are predicted in six of the seven mammalian *Nnat*proximal promoter regions examined here (all except rat), and are also present further upstream in the rat *Nnat*promoter region. Members of this family are expressed at reasonable levels in all three mouse tissues analysed here, so it remains possible that the *V\$NEUR*family participates in *Nnat*regulation in several tissues. *NeuroD1*is considered to be a weak activator of transcription, but is known to cooperate with other transcription factors, including *Rreb1*and *Sp1*\[[@B23],[@B26]\], in the stimulation of gene expression. Binding sites for both of these families are conserved in the *Nnat*promoter across mammalian species, as well as in the promoters for the *Nnat*co-varying genes analysed above. Indeed this property requires both the physical interaction of *Rreb1*with *NeuroD1*, and binding *of Rreb1*to DNA. Direct evidence for such a mechanism of regulation requires experimental validation. The expression of *Nnat*remains strong in the developing pituitary of *NeuroD1*knockout mice\[[@B14]\], so it is clear that different TFs (or combinations thereof) are likely to be of varying importance in regulating *Nnat*expression in different tissues.

*Pparγ*is both necessary and sufficient for adipocyte differentiation of fibroblast/pre-adipocyte cell lines\[[@B24]\] and the presence, in all the *Nnat*promoters analysed here, of *Pparγ*binding sites is consistent with it playing a role in regulation of *Nnat*expression in WAT. *Nnat*expression is strongly reduced in WAT of a mouse model in which a dominant negative version of *Pparγ*is expressed\[[@B17]\]. Activation of *Pparγ*with *Pparγ*agonists improves insulin signalling and decreases inflammation. This is consistent with the view that *Nnat*protects against toxins and is concerned with resolution of tissue injury. Indeed our unpublished results in 3T3L1 cells, where we have over expressed *Nnat*indicate an anti-inflammatory function. However there is currently no evidence on whether *Pparγ*plays a direct role in the regulation of *Nnat*. Likewise, in mice expressing an inactive mutant version of *Srebp1c*, *Nnat*expression in WAT is severely reduced as well\[[@B17]\]. In both of these mouse models complex changes in WAT gene expression make it difficult to draw conclusions as to the regulation of particular genes by specific TFs. *Pparγ*is known to operate in a cellular network with other TFs of the *EBF, C/EBP*, *KLF*and *IRF*families in regulating adipogenesis\[[@B24],[@B27]-[@B29]\]. Our bioinformatical analysis suggests that *Pparγ*could be a candidate for *Nnat*regulation, meanwhile the absence of *V\$SREB*binding sites in the *Nnat*promoter does not support a direct role for *Srebp1c*.

The pattern of gene expression observed in the mouse WAT upon high fat feeding in experiments analysed here suggests a critical in oxidative stress; indeed sentinel indicators of this *Gstt1, Ccdc80, Hfe*and *Sod3*all concerned with cellular management of free radicals are the genes most highly correlated with *Nnat*in the meta-analysis (Additional file [1](#S1){ref-type="supplementary-material"}, **Figure S3**). Genes concerned with adipogenesis (*Ebf1, Fzd4*and *Lgals12*) and inflammation (*Sncg, Cxcl9*and *Aoc3*) are also highly correlated in mouse WAT upon high fat feeding (Additional file [1](#S1){ref-type="supplementary-material"}, **Figure S2**). This is consistent with data indicating that *Nnat*expression favours adipogenesis and inflammation. Of the aforementioned adipogenic TFs, only *Ebf1*expression correlates well with *Nnat*, but the conserved *Nnat*promoter does not possess *Ebf1*binding sites (TF family *V\$NOLF*). Thus it is unlikely that *Ebf1*regulates *Nnat*expression; instead they may both be targets of the same TFs. By treating the *Nnat*co-varying genes as a set, and carrying out promoter analysis on this set, we discovered that many wide-acting TFs have binding sites in all of these genes. This does not itself indicate which, if any, of these TFs may regulate the *Nnat*co-varying genes, but does draw attention to the families *V\$HIFF*(example: *HIF1a*) *V\$RREB*(example: *Rreb1*) and *V\$TEAF*(example: *Tead4*) as being the most highly over-represented TFBS in this group of genes.

Our gene set enrichment analysis showed that expression of *Nnat*is strongly negatively correlated with energy metabolism (most notably oxidative phosphorylation) and positively correlated with inflammation. Repression of oxidative phosphorylation gene expression is one of the major changes seen in human diabetes\[[@B21]\], and a metabolic/inflammatory network is thought to underlie metabolic syndrome in susceptible mice\[[@B30]\]. Although in the human data *NNAT*expression is not correlated with oxidative phosphorylation in the GSEA in a more general analysis of gene expression in this human data the oxidative phosphorylation gene set is enriched. We would expect that major changes in gene set regulation require the participation of wide-acting TFs and/or extensive networks of TFs and their cofactors.

We found 27 genes that show strong co-variation with *Nnat*. 21 of these can be mapped to the PPI network, and eight of these (*Anxa6, Cav1, Cd151, Gstt1, Map1lc3a, Npdc1, Npr3, and Sncg*) are expressed in adipose tissue, pancreas and hypothalamus. *App*and *Tcf7l2*, genes implicated in metabolic inflammation, Alzheimer\'s disease and diabetes are shown linked to their respective first neighbours (Figure [2](#F2){ref-type="fig"}). *Sncg*along with *Nnat*is a leptin responsive gene\[[@B11]\].

Conclusions
===========

In conclusion we identify numerous TFBSs, conserved among mammals, on the *Nnat*promoter, and expression of TFs corresponding to these in adipose tissue, hypothalamus and pancreas. Many of these have known roles in adipocyte, as well as pancreatic and hypothalamic processes. We observe clustering of TFBSs for *Egr1*and *Tcf7l2*, which are implicated in stress responses and T2D; *E2f*which is concerned with adipogenesis and *Evi1*, a developmental gene highly expressed in pancreatic islets. GSEA analysis suggests the roles for *Nnat*in oxidative stress, resolution of inflammation, energy metabolism, mainly oxidative phosphorylation, and protein turnover. Genes that co-vary with *Nnat*, such as *Sncg, Gstt1, Hfe*and *Ebf1*, share some of these TFBSs and form functional networks. The recent demonstration that SNPs in *Nnat*are found in obese humans suggest that altered *Nnat*function in adipose tissue or the hypothalamus may be involved in the pathogenesis of obesity via such mechanisms.
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